ArticleOrphanet journal of rare diseases2026
Splicing defect and functional characterization of the ETFDH c.1049G > A VUS underlying transient MADD: an iPSC and minigene study.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInterpreting variants of uncertain significance (VUS) is challenging in patients with atypical or transient metabolic presentations.
methodsWe combined induced pluripotent stem cell (iPSC) models and minigene assays to characterize an ETFDH VUS (c.1049G > A) in a neonate who presented with acute metabolic decompensation characterized by fatty acid oxidation defects but showed normalized metabolic profiles by 14 months of age.
resultsPatient-derived iPSCs and minigene assays confirmed that c.1049G > A induces predominant exon 9 skipping, resulting in an in-frame 48-amino acid deletion within the FAD-binding domain. Structural modeling based on the human ETFDH crystal structure revealed that this deletion disrupts the core architecture of the FAD-binding domain, notably by eliminating the critical stabilizing interaction between Arg364 and Glu246, predicting compromised FAD binding affinity. Consistent with this structural defect, Western blot analysis showed markedly reduced ETFDH protein levels (< 10%) in patient cells versus heterozygous parents (~ 40%). Collectively, these data indicate that while the variant causes substantial molecular impairment explaining the neonatal crisis, the presence of residual protein likely supports metabolic homeostasis under non-stressful conditions.
conclusionsThe c.1049G > A variant causes significant splicing disruption and partial protein loss, explaining the transient nature of the neonatal decompensation rather than a classic, persistent MADD phenotype. Furthermore, this study underscores the utility of iPSC models in resolving VUS cases where clinical biochemistry normalizes over time, bridging the gap between ambiguous genetic data and precise clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.